ScreenerHero

SPRO Spero Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · sperotherapeutics.com
1.170USD-1.68%Mkt Cap: 68.13M $P/E: 8.36

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap68.13M USD
Enterprise Value20.57M USD
Revenue (TTM)47.00M USD
Gross Profit26.46M USD
Net Income (TTM)8.57M USD
Revenue/Share0.82 USD
Last Price1.170 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees25
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)8.36
P/E (Forward)-1.07
PEG—
EV/EBITDA—
EV/Revenue0.44
P/S1.47
P/B1.57
EPS (TTM)0.14
EPS (Forward)-1.11
52W Range
1.0804% of range3.080
52W High3.080 USD
52W Low1.080 USD
Profitability
Gross Margin56.31%
Oper. Margin14.07%
EBITDA Margin0.00%
Profit Margin14.38%
ROE14.52%
ROA12.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.62M USD
CapEx (TTM)—
FCF Margin61.38%
FCF Yield42.34%
Net Debt-48.73M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.05
Current Ratio6.12
Quick Ratio6.03
Book Value/Sh0.76 USD
Cash/Share0.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.000 USD
Upside (mean)+327.4%
Target Range4.000 USD – 6.000 USD
4.000+327.4% to mean6.000
# Analysts2
Ownership
Shares Out.58.23M
Float47.10M
Insiders22.66%
Institutions18.21%
Short Interest
Short Ratio2.6d
Short % Float2.02%
Short % Out.1.68%
Shares Short976.49K
Short (prev mo.)1.45M
Technical
SMA 501.202 (-2.7%)
SMA 2002.103 (-44.4%)
Beta1.50
S&P 52W Chg16.45%
Avg Vol (30d)717.50K
Avg Vol (10d)1.43M
Technical Indicators
RSI (14)43.9
MACD-0.0262
MACD Signal-0.0324
MACD Hist.+0.0062
BB Upper1.311 USD
BB Middle1.194 USD
BB Lower1.078 USD
BB Width19.48%
ATR (14)0.0724 USD
Vol Ratio (20d)0.26x